Clinical Relevance of Our Multimodality Prognostic Score

Affiliations

¹ Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
² Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland. Electronic address: walter.weder@usz.ch.

Free article

Comment

Isabelle Opitz et al. J Thorac Oncol. 2016 Mar.

Free article

. 2016 Mar;11(3):e39-40.

doi: 10.1016/j.jtho.2015.12.094.

¹ Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
² Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland. Electronic address: walter.weder@usz.ch.

No abstract available

Comment on

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.
Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim TD, Seifert B, Hoda MA, Klepetko W, Stahel RA, Weder W. Opitz I, et al. J Thorac Oncol. 2015 Nov;10(11):1634-41. doi: 10.1097/JTO.0000000000000661. J Thorac Oncol. 2015. PMID: 26317916 Review.
How Can We Use the Multimodality Prognostic Score?
Kataoka Y, Tsujimoto H, Tsujimoto Y. Kataoka Y, et al. J Thorac Oncol. 2016 Mar;11(3):e39. doi: 10.1016/j.jtho.2015.10.026. J Thorac Oncol. 2016. PMID: 26922921 No abstract available.